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Background and aims
Deletion of neuropeptide Y (NPY) Y2 and Y4 receptors
reduces anxiety-like and depression-related behaviour [1].
We have previously found that Y2 receptor knockout (Y2
-/
-) mice are particularly sensitive to the short-term anxio-
genic effect of immune stress evoked by systemic lipopol-
ysaccharide (LPS) [2]. In the present study we investigated
whether LPS challenge has long-term effects on anxiety-
like and depression-related behaviour and whether these
effects are altered in Y2
-/- and Y4
-/- mice.
Materials and methods
Adult control and germline Y2
-/- and Y4
-/- mice were used.
Anxiety-like behaviour was assessed on the elevated plus
maze, and depression-related behaviour was estimated
with the forced swim test. These tests were carried out 1
day or 4 weeks after a single intraperitoneal injection of
LPS (0.83 mg/kg) or vehicle (sterile saline).
Results
Relative to control animals, vehicle-treated Y2
-/- and Y4
-/-
mice were less anxious and displayed reduced depression-
like behaviour. One day after LPS injection, anxiety-like
behaviour remained unaltered in control animals but was
markedly enhanced in Y2
-/- and Y4
-/- mice. Four weeks
post-treatment, the anxiogenic effect of LPS was still seen
in Y4
-/-  mice but had gone in control and Y2
-/-  mice.
Depression-related behaviour was enhanced 1 day after
LPS treatment in control and Y2
-/- mice, but not in Y4
-/-
mice. Four weeks post-treatment, the effect of LPS chal-
lenge to increase depression-like behaviour had waned in
control mice, but was still present in Y2
-/- mice and was
first observed in Y4
-/- mice.
Conclusion
Y2
-/- and Y4
-/- mice are particularly susceptible to the effects
of immune stress to cause a long-term enhancement of
anxiety- and depression-like behaviour. With Y2 and Y4
receptors playing distinct roles in these persistent altera-
tions of emotional-affective behaviour, it is emerging that
endogenous NPY has an important bearing on immune
signalling to the brain.
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